Nathwani, AC;
Davidoff, AM;
Tuddenham, EGD;
(2017)
Gene Therapy for Hemophilia.
Hematology/Oncology Clinics of North America
, 31
(5)
pp. 853-868.
10.1016/j.hoc.2017.06.011.
Preview |
Text
Nathwani_Haemophilia Review v4.pdf - Accepted Version Download (423kB) | Preview |
Abstract
The best currently available treatments for hemophilia A and B (factor VIII or factor IX deficiency, respectively) require frequent intravenous infusion of highly expensive proteins that have short half-lives. Factor levels follow a saw-tooth pattern that is seldom in the normal range and falls so low that breakthrough bleeding occurs. Most hemophiliacs worldwide do not have access to even this level of care. In stark contrast, gene therapy holds out the hope of a cure by inducing continuous endogenous expression of factor VIII or factor IX following transfer of a functional gene to replace the hemophilic patient's own defective gene.
Archive Staff Only
 |
View Item |
